{
    "nctId": "NCT00445029",
    "officialTitle": "Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation",
    "inclusionCriteria": "For both groups:\n\n* Patients aged from 18 to 65 years old.\n* Both genders eligible for study.\n* Female participants must use a contraceptive method.\n* Feasibility of patch testing.\n* Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.\n* Patients must be registered in a social security system or with a health insurance coverage\n\n  \uf0d8 First group: allergic patients\n* Patients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests.\n\n  \uf0d8 Second group : healthy volunteers\n* No history of PPD allergic contact dermatitis, with a negative PPD patch test.\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* Pregnant or lactating women.\n* Evolutive skin disease on the testing zone (lower back).\n* Patients with a clinically significant disease (chronic, recurrent or active).\n* Systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid treatment the week before the patch testing.\n* Local or systemic drug use which interacts with the outcome measures.\n* Exposure to sun or UV radiations, 15 days before the patch testing.\n* Patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision.\n* Patients subject to a protection measure.\n* Patients in a critical medical situation.\n* Patients with a personal situation judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient.\n* Linguistic barrier or psychological profile preventing the patient from signing the consent form.\n* Patient still in an exclusion period following the participation in another clinical trial.\n* Patients having earned more than 4500\u20ac in indemnities for participation in clinical trials during the previous 12 months, including this study."
}